Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes.

Although the primary end point did not reach statistical significance, further analysis suggested improved mortality reductions for the MMS group compared to the control group after 7 years; 8% reduction for the first 7 years compared to 23% for years 7 to 14; suggesting a “late effect” mortality benefit[ 38 ].

also in 111,027 other papers